Kassi Filkins, Editor

This new QLS-111 and latanoprost fixed-dose combination (QLS-111-FDC; Qlaris) is in development for the treatment of primary open angle glaucoma, ocular hypertension, and normal tension glaucoma for patients whom optimal intraocular pressure control may remain “unachievable” due to needing to lower episcleral venous pressure.

This strategic investment will allow both companies to better serve the Canadian market.

New research reveals how low blood sugar can damage the retina in diabetes, highlighting potential treatments targeting specific proteins to prevent vision loss.

Topcon Healthcare launches IDHea, an innovative platform enhancing AI research and ocular data access to improve clinical outcomes in health care, alongside Cascader Limited, which was created in partnership with Moorfields Eye Hospital NHS Foundation Trust and the UCL Institute of Ophthalmology (IoO).

The company said it will be available on the US market for use in clinics and healthcare institutions.

The FDA did not agree with a supplemental Biologics License Application for the addition of extended dosing intervals of up to 24 weeks across currently-approved indications.

Catch up on what happened in optometry during the week of November 13-November 17.

Using the NEI protocol for addressing corneal staining, researchers used 5 microliters of 2%, non preserved fluorescein and then evaluated corneal staining.

Hear about the new innovations on the market—and coming soon—from Alcon.

Hear how this daily disposable silicone hydrogel option fits patients' busy and active lifestyles.

Hear how the Clek study continues to play a role in today's keratoconus care.

Catch up on what happened in optometry during the week of November 6-November 11.

Clark Chang, OD, MSA, MSC, FAAO, shares highlights from his 2023 AAOpt presentation, which he co-presented with Christine Sindt, OD, FAAO.

Catch up on what happened in optometry during the week of October 30-November 3.

Patients who have signs or symptoms of an eye infection after using these products should talk to their health care provider or seek medical care immediately.

Catch up on what happened in optometry during the week of October 23-October 27.

Catch up on what happened in optometry during the week of October 16-October 20.

Tracy Doll, OD, FAAO, shares an overview of her anterior segment symposium presented during the 2023 AAOpt annual meeting.

Learn what's in the pipeline for eSight, as well as hear how their current technology helps patients.

As new treatment options continue to enter the glaucoma space, clinicians can provide the best care to each individual patient.

Tracy Doll, OD, FAAO, chats about the AAOpt session "Sunny With a Chance of Tears: What's in the Forecast for Ocular Surface Dryness Therapies?"

Karen G. Carrasquillo, OD, PhD, FAAO, FSLS, FBCLA, shares highlights from her 2023 AAOpt presentations on scleral lenses, as well as cultural competency.

Therapies and technologies to treat allergic conjunctivitis are rapidly changing.

Catch up on what happened in optometry during the week of October 9-October 13.

Drs Paul Chous and Jeffry Gerson brought a new spin on the diabetes talk they've been presenting the last 18 years at the American Academy of Optometry annual meetings.

Over a dozen visual tests help clinicians identify patients who might benefit from vision therapy.

Ariel Cerenzie, OD, FAAO, FSLS, shares highlights from the recently released Contact Lens Institute report on contact lens culture.

Gleb Sukhovolskiy discusses his 2023 AAOpt presentation, "Optometrist’s Guide to MIGS and the Continuing Evolution of Glaucoma Treatment."